Literature DB >> 15867385

Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.

Valérie Gouazé1, Yong-Yu Liu, Carlton S Prickett, Jing Y Yu, Armando E Giuliano, Myles C Cabot.   

Abstract

Overexpression of glucosylceramide synthase (GCS), a pivotal enzyme in glycolipid biosynthesis, contributes to cancer cell resistance to chemotherapy. We previously showed that transfection of doxorubicin-resistant MCF-7-AdrR cells with GCS antisense restored cell sensitivity to doxorubicin and greatly enhanced sensitivity to vinblastine and paclitaxel. In that study, doxorubicin promoted generation of ceramide in MCF-7-AdrR/GCS antisense cells; the present study implicates factors in addition to ceramide that augment sensitivity to chemotherapy. Although GCS antisense cells showed enhanced ceramide formation compared with MCF-7-AdrR when challenged with paclitaxel, GCS antisense cells also showed a 10-fold increase in levels of intracellular drug (paclitaxel and vinblastine). In addition, transfected cells had dramatically decreased expression (80%) of P-glycoprotein and a 4-fold decrease in the level of cellular gangliosides. Chemical inhibition of GCS produced the same effects as antisense transfection: exposure of MCF-7-AdrR cells to the GCS inhibitor 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP, 5.0 micromol/L, 4 days) decreased ganglioside levels, restored sensitivity to vinblastine, enhanced vinblastine uptake 3-fold, and diminished expression of MDR1 by 58%, compared with untreated controls. A similar effect was shown in vinblastin-resistant KB-V0.01 cells; after 7 days with PPMP (10 micromol/L), MDR1 expression fell by 84% and P-glycoprotein protein levels decreased by 50%. MCF-7-AdrR cells treated with small interfering RNAs to specifically block GCS also showed a dramatic decrease in MDR1 expression. This work shows that limiting GCS activity down-regulates the expression of MDR1, a phenomenon that may drive the chemosensitization associated with blocking ceramide metabolism. The data suggest that lipids play a role in the expression of multidrug resistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15867385     DOI: 10.1158/0008-5472.CAN-04-2329

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  58 in total

1.  Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.

Authors:  Su-Fern Tan; Wendy Dunton; Xin Liu; Todd E Fox; Samy A F Morad; Dhimant Desai; Kenichiro Doi; Mark R Conaway; Shantu Amin; David F Claxton; Hong-Gang Wang; Mark Kester; Myles C Cabot; David J Feith; Thomas P Loughran
Journal:  J Lipid Res       Date:  2019-04-08       Impact factor: 5.922

Review 2.  Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.

Authors:  Lara Milane; Shanthi Ganesh; Shruti Shah; Zhen-Feng Duan; Mansoor Amiji
Journal:  J Control Release       Date:  2011-04-08       Impact factor: 9.776

3.  Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.

Authors:  Alicja Bielawska; Jacek Bielawski; Zdzislaw M Szulc; Nalini Mayroo; Xiang Liu; AiPing Bai; Saeed Elojeimy; Barbara Rembiesa; Jason Pierce; James S Norris; Yusuf A Hannun
Journal:  Bioorg Med Chem       Date:  2007-08-24       Impact factor: 3.641

4.  Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy.

Authors:  Gauri Patwardhan; Vineet Gupta; Juowen Huang; Xin Gu; Yong-Yu Liu
Journal:  Biochem Pharmacol       Date:  2010-03-16       Impact factor: 5.858

Review 5.  Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.

Authors:  Yong-Yu Liu; Ronald A Hill; Yu-Teh Li
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

Review 6.  Interdiction of sphingolipid metabolism to improve standard cancer therapies.

Authors:  Thomas H Beckham; Joseph C Cheng; S Tucker Marrison; James S Norris; Xiang Liu
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

7.  Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism.

Authors:  Kristin Gustafsson; Birgitta Sander; Jacek Bielawski; Yusuf A Hannun; Jenny Flygare
Journal:  Mol Cancer Res       Date:  2009-07       Impact factor: 5.852

8.  Ceramide signaling in cancer and stem cells.

Authors:  Erhard Bieberich
Journal:  Future Lipidol       Date:  2008-06

9.  Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.

Authors:  Yong-Yu Liu; Vineet Gupta; Gauri A Patwardhan; Kaustubh Bhinge; Yunfeng Zhao; Jianxiong Bao; Harihara Mehendale; Myles C Cabot; Yu-Teh Li; S Michal Jazwinski
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

10.  A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis.

Authors:  Gauri A Patwardhan; Qian-Jin Zhang; Dongmei Yin; Vineet Gupta; Jianxiong Bao; Can E Senkal; Besim Ogretmen; Myles C Cabot; Girish V Shah; Paul W Sylvester; S Michal Jazwinski; Yong-Yu Liu
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.